2. Academic Validation
  3. Novel Tricyclic Heteroaryl Compounds as IRAK4 Inhibitors for Treating Cancer, Autoimmune and Inflammatory Diseases

Novel Tricyclic Heteroaryl Compounds as IRAK4 Inhibitors for Treating Cancer, Autoimmune and Inflammatory Diseases

  • ACS Med Chem Lett. 2022 Feb 28;13(3):336-337. doi: 10.1021/acsmedchemlett.2c00060.
Ram W Sabnis 1
Affiliations

Affiliation

  • 1 Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
PMID: 35300088 DOI: 10.1021/acsmedchemlett.2c00060
Figures
Products